Status: Partnerships and initiatives

iiCON and the Liverpool School of Tropical Medicine: A partnership tackling emerging viral threats and neglected tropical diseases

A £2.7 million Translational Development Fund to support the development of new diagnostics and treatments.

Mike with Prof Janet Hemingway and her associate, all in business casual clothing with hands folded in front

Overview

The Translational Development Fund was launched in partnership with the Liverpool School of Tropical Medicine (LSTM) to support the development of diagnostics and treatments. We also joined the LSTM-led Infection Innovation Consortium (iiCON) to accelerate the discovery and development of new therapies and innovations.

About the Translational Development Fund

We are partnering with the Liverpool School of Tropical Medicine (LSTM) to launch a new £2.7 million Translational Development Fund. This fund will support the development of diagnostics and treatments to tackle emerging viral threats and neglected tropical diseases.

Who is the fund available to?

The fund will be available to all of LSTM’s partners, including research organisations in low-and-middle-income countries.

Infection Innovation Consortium (iiCON)

We have also joined the LSTM-led Infection Innovation Consortium (iiCON), alongside other core partners such as Unilever, Evotec, the Liverpool University Hospitals Foundation Trust, the University of Liverpool, and Infex Therapeutics. The aim of the £250 million programme is to accelerate the discovery and development of new therapies and innovations.

iiCON agreement

As part of this agreement, we have made our antibody humanisation platform available for iiCON and its partners to support the development of new potential treatments. The Translational Development Fund will also be available to iiCON and its collaborators.

Related stories